How to navigate early clinical development and support robust registrational strategy and late-stage development in oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The clinical development strategy in oncology during the last decade has been substantially affected in several ways by the advent of immunotherapy1, and more recently, cell and gene therapy2 treatment options. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Tanja Obradovic, PhD
Vice president, Scientific Affairs, Medical Affairs Oncology, ICON Biotech
Table of Contents

YOU MAY BE INTERESTED IN

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
Tanja Obradovic, PhD
Vice president, Scientific Affairs, Medical Affairs Oncology, ICON Biotech

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login